Business context and reporting period
The supplied filing is OncoCyte Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2016, not a filing identified as Insight Molecular Diagnostics Inc. OncoCyte, a majority-owned BioTime subsidiary, was developing molecular cancer diagnostics, with a focus on lung, bladder, and breast cancer tests. It had generated no revenue.
Financial performance and position
- Revenue and profit: No revenue. Net loss was $2.93 million, versus $1.37 million in Q1 2015; loss per share was $0.12 versus $0.08. No income tax provision or benefit was recorded.
- Expenses: R&D was $1.69 million, up 51% year over year; general and administrative expense was $1.24 million, up 397%. The filing attributes increased R&D chiefly to outside research, scientific consulting, and clinical trial costs, and higher G&A to staffing, consulting, audit/compliance, and public-company costs.
- Cash flow: Operating cash used was $2.17 million, compared with $0.16 million in Q1 2015. Investing cash use was $15,000; option exercises provided $42,000. Cash declined by $2.14 million to $5.86 million.
- Liquidity and liabilities: Cash plus BioTime shares held as available-for-sale securities totaled approximately $7.64 million at quarter-end; current liabilities were $2.75 million. Liabilities were current, including $1.32 million due to BioTime and $152,000 due to affiliates. No long-term debt was reported at March 31.
- Other measures: Total assets were $9.65 million and accumulated deficit was $27.06 million. BioTime shares were valued at $1.78 million, down from $2.54 million at year-end; the quarter’s unrealized loss was $762,000 and contributed to comprehensive loss of $3.69 million.
Material changes versus the prior comparable period
- Net loss more than doubled, while operating cash use rose substantially. Operating expenses increased from $1.37 million to $2.93 million.
- R&D spending shifted toward lung diagnostics: lung-test expenses rose to $805,000 from $27,000, while bladder and breast program spending declined year over year.
- Weighted-average shares rose to 25.40 million from 18.20 million; the filing reports 25.43 million shares outstanding as of May 9, 2016.
Outlook, risks, and unusual items
- Management expected available cash and securities to fund ongoing operations through December 31, 2016, based on projected spending. Additional capital would be needed to establish a certified diagnostic laboratory and commercialize tests; financing availability and terms were uncertain.
- Management expected continued R&D spending, operating losses, and negative cash flows. Additional equity financing could dilute shareholders, and inadequate financing could force operations to be modified, delayed, or curtailed.
- On April 7, 2016, after quarter-end, OncoCyte entered a laboratory-equipment capital lease with a net present value of $464,000, payable at $14,442 monthly for 36 months.
- BioTime provided shared facilities, personnel, and services; amounts payable to BioTime and affiliates were approximately $1.5 million at quarter-end. The filing reports no material litigation, no off-balance-sheet arrangements, and no material changes in market risk.
Investor verification points
- Confirm the issuer: the supplied document is OncoCyte Corporation’s filing, despite the request naming Insight Molecular Diagnostics Inc.
- Check the pace of cash burn, the assumptions behind management’s runway estimate through year-end 2016, and the timing and terms of additional financing.
- Verify progress, costs, and commercialization plans for the lung diagnostic and any proposed laboratory build-out.
- Review the BioTime service allocations and related-party balances, and the capital lease’s impact on future cash requirements.
- Assess the valuation and potential working-capital use of the BioTime shareholding, including the effect of price changes.